The number of drugs developed in Turku, Finland, and granted marketing authorizations this year now stands at three, with a fourth expected to follow.
The number of drugs developed in Turku, Finland, and granted marketing authorizations this year now stands at three, with a fourth expected to follow.
The FDA granted market authorization for the IUD Skyla, developed by Bayer and intended for women who have not given birth, and Hormos Medical’s Ophena for postmenopausal symptoms. The European MedicinesAgency authorized Selincro, a Biotie drug intended for the treatment of alcohol addiction.
Only about 30 new drugs receive marketing authorization in Europe each year, making the Turku turnout even more remarkable.
Further information
